Emil Larsson’s Post

View profile for Emil Larsson, graphic

Providing Talent Solutions in Medical Imaging & AI

Breaking news 🧠 Eli Lilly and Company Kisunla™ is FDA approved for the treatment of early symptomatic Alzheimer's disease, offering patients a way to slow the disease's progression, and improve their quality of life. "Kisunla demonstrated very meaningful results for people with early symptomatic Alzheimer's disease, who urgently need effective treatment options. We know these medicines have the greatest potential benefit when people are treated earlier in their disease, and we are working hard in partnership with others to improve detection and diagnosis," said Anne White, and President of Lilly Neuroscience International Medical Imaging companies play a critical role in the analysis of brain scans for Neurodegenerative disease markers. Aside from the big names, younger companies like Qynapse, Cortechs.ai, icometrix, Oxford Brain Diagnostics Ltd, Darmiyan , Vistim Labs and others work tirelessly to support the positive patient impact of drugs like Kisunla! #earlydetection #medicalimaging #artificialintelligence

To view or add a comment, sign in

Explore topics